Navigation Links
Diabetes slows nerve recovery after heart transplant

Diabetes has a detrimental effect on a person's ability to recover from a heart transplant, notes a study in the September Journal of Nuclear Medicine.

"Using positron emission tomography (PET) and the transplanted heart as a very specific model to study the regenerative capacity of the heart's sympathetic nervous system, we determined that reinnervation--or the heart's ability to develop new nerves to replace damaged ones--is slower in diabetic patients," said Frank M. Bengel, a visiting associate professor of radiology and the director of cardiovascular nuclear medicine at Johns Hopkins Medicine's Russell H. Morgan Department of Radiology and Radiological Science in Baltimore, Md. "Our results confirm a detrimental effect of diabetes on the potential for recovery of sympathetic nerve fibers of the heart," added the co-author of "Effect of Diabetes Mellitus on Sympathetic Neuronal Regeneration Studied in the Model of Transplant Reinnervation."

"A better understanding of the importance of nervous system abnormalities and an imaging technique to precisely characterize nerve damage may be of value to guide future therapeutic efforts aimed at reducing cardiac risk with diabetes mellitus patients," explained Bengel, who was an associate professor at the Technical University of Munich, where the study was performed, prior to his move to Johns Hopkins. "Even if a transplant recipient is suffering from diabetes, there is still a chance for reinnervation--just at a slower speed," he added. "Unfortunately, there are no techniques developed yet that speed the nerve regeneration process," he said.

Currently, nuclear medicine techniques (such as PET) are the only imaging techniques that can measure the presence and function of the sympathetic nervous system of the heart, said Bengel. "There are invasive methods that allow for the measurement of neurotransmitters released to the blood, offering indirect conclusions about the presence, storage and releas e of neurotransmitters from neurons. These methods require complicated and laborious sampling of blood from coronary arteries and veins," he added.

Diabetes mellitus is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Such a deficiency results in increased concentrations of glucose (sugar) in the blood, which can damage many of the body's systems. Diabetes mellitus is a known major risk factor of heart disease, negatively affecting the heart's contraction and rhythm, said Bengel.

Future research will need to focus on how regeneration of sympathetic nerves can be facilitated and how changes of the sympathetic nerve integrity in the heart are interrelated with changes of prognosis and outcome of diseases like diabetes mellitus, said Bengel.

"Effect of Diabetes Mellitus on Sympathetic Neuronal Regeneration Studied in the Model of Transplant Reinnervation" appears in the September issue of the Journal of Nuclear Medicine, which is published by SNM. Other co-authors include Peter Ueberfuhr and Bruno Reichart, Ludwig-Maximilians University in Munich, Germany; and Dominik Schäfer, Stephan G. Nekolla and Markus Schwaiger, all with the Technical University of Munich, Germany.
'"/>

Source:Society of Nuclear Medicine


Related biology news :

1. FDA Approves New Drug to Treat Type I and Type II Diabetes
2. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
3. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
4. Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes
5. Diabetes researchers pioneer islet cell xenotransplantation in primate studies
6. Diabetes hits 275 Australians each day as pandemic spreads
7. Diabetes research takes wing thanks to long-lived fruit fly
8. Cancer drug slows poxvirus in mice
9. Stress substantially slows human bodys ability to heal
10. Cell therapy slows progression of an inherited neurological disease; Improves motor skills in mice
11. Protein found that slows hepatitis C growth in liver cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017  Atrius Health and ... entered into an agreement to develop a cloud ... By providing a holistic view of the multiple ... Watson Cognitive Insights could be designed to support ... Health is an innovative nonprofit healthcare organization with ...
(Date:2/18/2017)... Feb 17, 2017 Research and Markets has ... Report" report to their offering. ... The report provides separate comprehensive analytics for ... , and Rest of World. Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today presented ... drug candidates, PTG-100 and PTG-200, at the 12 ... Colitis Organization (ECCO).  The ECCO congress is being ... from February 15 – 18, 2017. ... drug candidates PTG-100 and PTG-200. PTG-100, a potential ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
Breaking Biology Technology: